Complement proteins C2, C4 and factor B. Effect of glycosylation on their secretion and catabolism.
Tunicamycin, an inhibitor of N-acetylglucosaminylpyrophosphopolyisoprenol-dependent glycosylation, was used to study the effect of glycosylation on the synthesis, post-translational modification, secretion and function of the complement proteins that are associated with the major histocompatibility complex in humans, mice and guinea pigs. Tunicamycin blocked glycosylation of pro-C4, C2 and factor B and inhibited secretion of the corresponding native complement proteins synthesized by guinea-pig peritoneal macrophages in tissue culture. In addition, underglycosylated pro-C4 was more rapidly catabolized intracellularly than the corresponding fully glycosylated pro-complement protein. C4 protein secreted by cells incubated with tunicamycin had approximately the same specific biological activity as the protein obtained from control culture media, suggesting that carbohydrate is not required for its activity in immune haemolysis. Direct studies of carbohydrate incorporation and the tunicamycin effect suggested an unequal distribution of sugar among the C4 subunits, with maximal incorporation of carbohydrate into alpha-, and less into the beta-chain of the native protein.
D000818:Animals; D001202:Ascitic Fluid / Q000166:cytology; D050260:Carbohydrate Metabolism; D002478:Cells, Cultured; D003175:Complement C2 / Q000378:metabolism*; D003181:Complement C4 / Q000378:metabolism*; D011415:Complement Factor B / Q000378:metabolism*; D004591:Electrophoresis, Polyacrylamide Gel; D004792:Enzyme Precursors / Q000378:metabolism*; D006168:Guinea Pigs; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism; D011498:Protein Precursors / Q000378:metabolism; D014415:Tunicamycin / Q000494:pharmacology
D003175:Complement C2; D003181:Complement C4; D004792:Enzyme Precursors; D011498:Protein Precursors; D014415:Tunicamycin; D011415:Complement Factor B